CSIMarket
 


Biogen Inc   (BIIB)
Other Ticker:  
 

Biogen Inc 's Total Debt to Equity

BIIB's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to debt repayement of -4.78% Biogen Inc improved Total Debt to Equity in forth quarter 2023 to 0.47, above the Biogen Inc 's average Total Debt to Equity.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2023, 4 other companies have achieved lower Total Debt to Equity than Biogen Inc in the IV Quarter 2023. While Total Debt to Equity total ranking has improved so far in the forth quarter 2023 to 584, from total ranking in the third quarter 2023 at 1187 .

Explain Debt to Equity Ratio?
What is the structure of BIIB´s Total Debt?
How valuable is the BIIB´s Equity?


BIIB Total Debt to Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 10.54 % 13.42 % 21.89 % 22.87 % 22.16 %
Y / Y Total Debt Change 10.46 % 16.04 % -13.64 % -13.64 % -13.64 %
Total Debt to Equity MRQ 0.47 0.5 0.43 0.46 0.47
BIIB's Total Ranking # 584 # 1187 # 1238 # 56 # 1436
Seq. Equity Change 2.21 % 0.13 % 4.89 % 2.98 % 4.87 %
Seq. Total Debt Change -4.78 % 15.94 % 0.03 % 0.03 % 0.03 %



Total Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 59
Overall Market # 584


Total Debt to Equity Statistics
High Average Low
0.7 0.3 0
(Dec 31 2015)   (June 30. 2013)




Financial Statements
Biogen Inc 's Equity $ 14,799 Millions Visit BIIB's Balance sheet
Biogen Inc 's Total Debt $ 6,938 Millions Visit BIIB's Balance sheet
Source of BIIB's Sales Visit BIIB's Sales by Geography


Cumulative Biogen Inc 's Total Debt to Equity

BIIB's Total Debt to Equity for the trailling 12 Months

BIIB Total Debt to Equity

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth 10.54 % 13.42 % 21.89 % 22.87 % 22.16 %
Y / Y Total Debt TTM Growth 10.46 % 16.04 % -13.64 % -13.64 % -13.64 %
Total Debt to Equity TTM 0.47 0.47 0.46 0.5 0.55
Total Ranking TTM # 55 # 68 # 98 # 73 # 1260
Seq. Equity TTM Growth 2.21 % 0.13 % 4.89 % 2.98 % 4.87 %
Seq. Total Debt TTM Growth -4.78 % 15.94 % 0.03 % 0.03 % 0.03 %


On the trailing twelve months basis Due to debt repayement of -4.78% Biogen Inc has not changed Total Debt to Equity in the 12 months ending in IV Quarter 2023 to 0.47, above the Biogen Inc 's average Total Debt to Equity.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 2, during the past 12 months, other companies have achieved lower Total Debt to Equity than Biogen Inc . While Total Debt to Equity total ranking has improved so far to 55, from total ranking in previous 12 month period at 68.

Explain Debt to Equity Ratio?
What is the structure of BIIB´s Total Debt?
How valuable is the BIIB´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 3
Healthcare Sector # 14
Within the Market # 55


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.68 0.25 0
(Mar 31 2021)   (Dec. 30, 2015)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Total Debt to EquityDec 31 2023 MRQ Total DebtDec 31 2023 MRQ Equity
Gilead Sciences Inc   1.10 $ 24,987.000  Millions$ 22,749.000  Millions
Valneva Se  1.04 $ 148.789  Millions$ 143.637  Millions
Adma Biologics Inc   0.97 $ 130.594  Millions$ 135.206  Millions
Protalix Biotherapeutics inc   0.60 $ 20.251  Millions$ 33.569  Millions
Elevation Oncology inc   0.55 $ 30.137  Millions$ 54.809  Millions
Meiragtx Holdings Plc  0.52 $ 72.119  Millions$ 138.177  Millions
Biogen Inc   0.47 $ 6,938.200  Millions$ 14,799.400  Millions
Qiagen N v   0.40 $ 1,509.794  Millions$ 3,807.764  Millions
Coeptis Therapeutics Holdings Inc   0.26 $ 1.125  Millions$ 4.314  Millions
Bio techne Corp  0.23 $ 447.000  Millions$ 1,963.559  Millions
Scholar Rock Holding Corp  0.22 $ 50.018  Millions$ 225.218  Millions
Tarsus Pharmaceuticals Inc   0.15 $ 29.819  Millions$ 196.988  Millions
Immunocore Holdings Plc  0.13 $ 48.011  Millions$ 368.843  Millions
Acumen Pharmaceuticals Inc   0.11 $ 29.897  Millions$ 266.973  Millions
Replimune Group Inc   0.11 $ 44.434  Millions$ 421.537  Millions

Date modified: 2024-02-16T23:53:59+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com